New York City health officials have confirmed the city’s first severe mpox case tied to clade I, with the patient testing positive after recent travel. Clade I is a genetically distinct group known for causing more serious illness than the clade behind the 2022 global outbreak. Authorities say there is no evidence of local spread so far, and they are urging at-risk people to consider vaccination.
One New York resident tested positive for mpox clade I, the strain linked to higher severity in prior outbreaks. That contrasts with clade II, which drove the 2022 worldwide wave and is associated with survival rates above 99.9 percent. Public health teams are treating this as an importation event and monitoring contacts closely.
“Clade I causes more severe symptoms and can be life-threatening,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital. The virus spreads through direct skin-to-skin contact, intimate contact during sex, kissing, and very close respiratory droplets, so close personal interactions are the real risk. Casual contact in public spaces is much less likely to transmit the infection.
“This appears to have come here from travel and has not spread locally,” Siegel noted, and city officials echo that assessment while remaining vigilant. The patient had recently traveled outside the United States, which aligns with the travel-linked pattern investigators found. Contact tracing is underway to identify anyone who might need monitoring or prophylaxis.
“The NYC Health Department recommends that New Yorkers who are at risk for mpox receive and complete the two-dose vaccine series that works to prevent mpox,” he said in a statement. Federal guidance also targets vaccination toward men who are gay, bisexual or have sex with men and who are 18 or older with specific exposure risks. Travelers heading to regions where clade I is circulating are advised to get vaccinated before departure.
Anyone who may have had close contact with an infected person should seek vaccination within 14 days to reduce the chance of disease or blunt symptoms if infection occurs. The two-dose JYNNEOS vaccine is the most commonly used option and is designed to give reliable protection when the series is completed. People who have already had mpox are generally not recommended to be vaccinated.
Mpox typically begins with fever, chills, exhaustion, muscle aches, and swollen lymph nodes, then progresses to a sometimes painful blistery rash on various parts of the body. Symptoms usually show up one to three weeks after exposure, which can complicate efforts to spot and isolate cases quickly. Respiratory symptoms can appear in some cases but are not the primary mode of spread for this virus.
In uncommon but serious cases, mpox may cause eye infections that threaten vision, widespread or severely painful skin lesions, and neurological complications that require urgent care. People with weakened immune systems and very young children are at the highest risk of developing severe illness. Those groups should be prioritized for prevention and rapid treatment if exposed.
Treatment for mpox centers on supportive care to manage pain, fever, and secondary infections, while severe cases may be treated with antiviral medication. TPOXX, or tecovirimat, is an antiviral that clinicians can use for severe mpox because it targets viruses related to smallpox. Health providers are prepared to use available antivirals and supportive therapies when a patient’s condition warrants extra intervention.
